```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:15:24 ON 22 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Oct 2002  VOL 137 ISS 17
FILE LAST UPDATED: 21 Oct 2002  (20021021/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=>
=>

=> d stat que
L1              STR
```




```
VAR G2=16/18/21/24/25/27/29/31/32
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE
L2 241 SEA FILE=REGISTRY SSS FUL L1
L3 STR



REP G1=(0-1) N
VAR G2=16/18/21/24/25/27/29/31/32
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE
L4 (241) SEA FILE=REGISTRY SSS FUL L3
L5 STR



REP G1=(0-1) N
VAR G2=16/18/21/24/25/27/29/31/32
VAR G3=39/46/47/48
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE

L6	100	SEA	FILE=REGISTRY	SUB=L4	SSS FUL	L5
L10	12	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L2
L11	3	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L6
L12	9	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L10 NOT L11

=>
=>

=> d ibib abs hitstr l12 1-9

L12 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:72030 HCAPLUS
DOCUMENT NUMBER: 136:134761
TITLE: Preparation of 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acids as inhibitors of matrix metallo-proteinases (MMPs)
INVENTOR(S): Mantegani, Sergio; Bissolino, Pierluigi; Abrate, Francesca; Cremonesi, Paolo; Perrone, Ettore
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006215	A1	20020124	WO 2001-EP7736	20010705

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-17435 A 20000714

OTHER SOURCE(S): MARPAT 136:134761

GI



I

AB The title compds. [I; X = NHOH, OH; R1 = OPh, SPh, SHet, Hyd, CH2Hyd; Het = heterocyclic ring; Hyd = substituted hydantoin-3-yl ring; A = Ph, Het, condensed Ph ring; R2 = H, Me; or R2 represents a methylene bridge connecting the N atom to the ortho position of said A to form a 5-membered lactam] or their salts which are inhibitors of matrix metallo-proteinases (MMPs) and are therefore useful in the prevention, control and treatment of diseases in which MMPs are involved, were prepd. E.g., a multi-step synthesis of I [A = 4-ClC6H4; X = OH; R1 = (3,4,4-trimethylhydantoin-1-yl)CH2; R2 = H] which showed Ki of 14.7 nM against MMP-2, was given.

IT **391903-55-2P 391903-56-3P 391903-57-4P**
391903-58-5P 391903-59-6P 391903-60-9P
391903-61-0P 391903-62-1P 391903-63-2P
391903-64-3P 391903-65-4P 391903-66-5P
391903-67-6P 391903-68-7P 391903-69-8P
391903-70-1P 391903-71-2P 391903-72-3P
391903-73-4P 391903-74-5P 391903-75-6P
391903-76-7P 391903-77-8P 391903-78-9P
391903-79-0P 391904-13-5P 391904-15-7P
391904-16-8P 391904-18-0P 391904-19-1P
391904-22-6P 391904-23-7P 391904-24-8P
391904-25-9P 391904-26-0P 391904-27-1P
391904-28-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acids as inhibitors of matrix metallo-proteinases (MMPs))

RN 391903-55-2 HCAPLUS

CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-56-3 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)



RN 391903-57-4 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[(4-pyridinylcarbonyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-58-5 HCAPLUS
CN Propanoic acid, 3-[[4-[(1,3-benzodioxol-5-ylcarbonyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-59-6 HCAPLUS
CN Propanoic acid, 3-[[4-[[4-(dimethylamino)benzoyl]amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391903-60-9 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-61-0 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-62-1 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-cyanobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-63-2 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[(4-pyridinylcarbonyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-64-3 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-bromobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-65-4 HCAPLUS
CN Propanoic acid, 3-[[4-[[4-(dimethylamino)benzoyl]amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391903-66-5 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]methyl]-3-phenoxy- (9CI) (CA INDEX NAME)



RN 391903-67-6 HCAPLUS
CN Propanoic acid, 3-[[4-[(1,3-benzodioxol-5-ylcarbonyl)amino]phenyl]sulfonyl

]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-68-7 HCAPLUS
CN Propanoic acid, 3-[[4-(benzoylamino)phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-69-8 HCAPLUS
CN Propanoic acid, 3-[[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-70-1 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)methylamino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-71-2 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-thiazolylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-72-3 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-73-4 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[[(4-hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 391903-74-5 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-[[(4-fluorophenyl)thio]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 391903-75-6 HCAPLUS
CN Benzamide, 4-chloro-N-[4-[[2-hydroxy-3-(hydroxyamino)-3-oxo-2-(phenoxymethyl)propyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 391903-76-7 HCAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 391903-77-8 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[[4-(trifluoromethoxy)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-78-9 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-79-0 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[[(4-hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 391904-13-5 HCAPLUS
CN Propanoic acid, 3-[[4-[(1H-benzotriazol-5-ylcarbonyl)amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391904-15-7 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391904-16-8 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-thiazolylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391904-18-0 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-pyridinylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391904-19-1 HCAPLUS
CN Propanoic acid, 3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391904-22-6 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[[4-(1-pyrrolidinyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-23-7 HCAPLUS
CN Propanoic acid, 3-[[4-[[(6-chloro-3-pyridinyl)carbonyl]amino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391904-24-8 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[(4-propoxybenzoyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-25-9 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[[4-(trifluoromethoxy)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-26-0 HCAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-27-1 HCAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-3-oxo-2-(phenoxymethyl)propyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 391904-28-2 HCAPLUS
CN Propanamide, 3-[[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)phenyl]sulfonyl]-N,2-dihydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:788776 HCAPLUS
DOCUMENT NUMBER: 130:52234
TITLE: Preparation of .beta.-benzenesulfonyl hydroxamic acids as inhibitors of matrix metalloproteinases involved in

CN Propanamide, 3-[(4-chlorophenyl)sulfonyl]-2-[[(4-chlorophenyl)sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 205504-42-3 HCAPLUS
CN Propanamide, 3-[(4-bromophenyl)sulfonyl]-2-[[(4-bromophenyl)sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 205504-45-6 HCAPLUS
CN Propanamide, N-hydroxy-3-[(4-methylphenyl)sulfonyl]-2-[[(4-methylphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-46-7 HCAPLUS
CN Propanamide, N-hydroxy-3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



RN 205504-49-0 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

tissue degradation
INVENTOR(S): Warpehoski, Martha A.; Harper, Donald E.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: U.S., 19 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5847153	A	19981208	US 1997-934408	19970919

OTHER SOURCE(S): MARPAT 130:52234
GI


I


II

AB The title compds. [I; R1 = C4-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; R2 = (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, etc.], inhibitors of matrix metalloproteinases involved in tissue degrdn. such as stromelysin, collagenase and gelatinase, and therefore useful in the treatment of osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenia, osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal epidermal ulceration or gastric ulceration, were prepd. Thus, 6-step synthesis of the title compd. II, starting with benzylmalonic acid di-Et ester, which showed Ki of 0.049 .mu.M and 0.0092 .mu.M against stromelysin and gelatinase, resp., was described.

IT **205504-40-1P 205504-41-2P 205504-42-3P**
205504-45-6P 205504-46-7P 205504-49-0P
205504-50-3P 205504-51-4P 205504-52-5P
205504-55-8P 205504-56-9P 205504-57-0P
205504-58-1P 205504-59-2P 205504-60-5P
205504-61-6P 205504-62-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .beta.-benzenesulfonyl hydroxamic acids as inhibitors of matrix metalloproteinases involved in tissue degrdn.)

RN 205504-40-1 HCAPLUS
CN Propanamide, N-hydroxy-3-[(4-methoxyphenyl)sulfonyl]-2-[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-41-2 HCAPLUS



RN 205504-50-3 HCAPLUS
CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-51-4 HCAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-52-5 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-55-8 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-56-9 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 205504-57-0 HCAPLUS
CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-58-1 HCAPLUS
CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 205504-59-2 HCAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-60-5 HCAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 205504-61-6 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-62-7 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT **205504-67-2P 205504-68-3P 205504-70-7P**
205504-74-1P 205504-87-6P 205504-88-7P
205504-90-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of .beta.-benzenesulfonyl hydroxamic acids as inhibitors of matrix metalloproteinases involved in tissue degrdn.)

RN 205504-67-2 HCAPLUS
CN Propanoic acid, 3-[(4-methoxyphenyl)thio]-2-[[(4-methoxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 205504-68-3 HCAPLUS
CN Propanoic acid, 3-[(4-methoxyphenyl)sulfonyl]-2-[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-70-7 HCAPLUS

CN Propanoic acid, 3-[(4-chlorophenyl)sulfonyl]-2-[[(4-chlorophenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-74-1 HCAPLUS
CN Propanoic acid, 3-[(4-methylphenyl)sulfonyl]-2-[[(4-methylphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-87-6 HCAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-methoxyphenyl)thio]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-88-7 HCAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-90-1 HCAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-2,5-dioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:414737 HCAPLUS
DOCUMENT NUMBER: 129:67777
TITLE: Preparation of antivirial 5,5-disubstituted hydantoins
INVENTOR(S): Comber, Robert N.; Reynolds, Robert C.; Buckheit, Robert W., Jr.
PATENT ASSIGNEE(S): Southern Research Institute, USA
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 945,208,

abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5767140	A	19980616	US 1995-403339	19950314

PRIORITY APPLN. INFO.: US 1992-945208 19920915
OTHER SOURCE(S): MARPAT 129:67777
GI



I

AB A series of 5,5-disubstituted hydantoin derivs. I (R, R1 = thiomethyl cyclic, thioaliph., thioalkyl cyclic) were synthesized by alkylating 5,5-bis(thiomethyl)-2,4-imidazolidinedione with halomethyl arom. or halomethyl heteroarom. precursors or by using the Buchener-Berg procedure on the required ketone. This series of 5,5-disubstituted Hydantoin derivs. are biol. active in their ability to inhibit HIV-induced death and virus prodn. in mammalian (human) cells. Thus, 5,5-bis(thiomethyl)-2,4-imidazolidinedione was treated with (bromomethyl)cyclohexane to give 5,5-bis[[[(cyclohexylmethyl)methyl]thio]methyl]-2,4-imidazolidinedione (II). The antivirial TC25 of II against CEM cell lines was 8 .mu.M.

IT **208828-00-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of antivirial 5,5-disubstituted hydantoins)

RN 208828-00-6 HCAPLUS
CN Cysteine, S-phenyl-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:208523 HCAPLUS
DOCUMENT NUMBER: 128:270437
TITLE: Preparation of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
INVENTOR(S): Warpehoski, Martha A.; Harper, Donald E.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA; Warpehoski, Martha A.; Harper, Donald E.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813340	A1	19980402	WO 1997-US16348	19970919
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9746459	A1	19980417	AU 1997-46459	19970919
AU 726799	B2	20001123		
EP 929519	A1	19990721	EP 1997-945207	19970919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
BR 9712134	A	19990831	BR 1997-12134	19970919
CN 1230177	A	19990929	CN 1997-197922	19970919
JP 2001516338	T2	20010925	JP 1998-515702	19970919
NO 9901494	A	19990526	NO 1999-1494	19990326
KR 2000048639	A	20000725	KR 1999-702581	19990326
US 6235928	B1	20010522	US 1999-269185	19990726

PRIORITY APPLN. INFO.: US 1996-26848P P 19960927
WO 1997-US16348 W 19970919

OTHER SOURCE(S): MARPAT 128:270437

AB HONHCOCHR2CH2SO2R1 [R1 = C4-12 alk(en)yl, C4-12 alkynyl, (CH2)hC3-8 cycloalkyl, (un)substituted (CH2)haryl, cyano, etc.; R2 = (un)substituted C1-12 alkyl, (un)substituted C2-12 alkenyl or alkynyl, (un)substituted (CH2)hC3-8cycloalk(en)yl, (un)substituted (CH2)haryl, etc.; h = 0-6] or their pharmaceutical acceptable salts were prepd. as inhibitors of matrix metalloproteinases involved in tissue degrdn. For example, refluxing 12 mmol 2-(bromomethyl)acrylic acid overnight with 27 mmol p-MeC6H4SO2Na.cntdot.H2O in 50 mL PhMe in the presence of 12 mmol NaHCO3 gave 2-[(4-methylbenzenesulfonyl)methyl]-3-(4-methylbenzenesulfonyl)propionic acid which (11 mmol) was stirred overnight with 22 mmol 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl and 22 mmol HONH2.cntdot.HCl in 20 mL N-methylpyrrolidone to give a title compd. p-MeC6H4SO2CH2CH(CONHOH)CH2SO2C6H4Me-p. The latter in vitro inhibited stromelysin and gelatinase with Ki 0.13 .mu.M and 0.0038 .mu.M, resp.

IT **205504-40-1P 205504-41-2P 205504-42-3P**
205504-45-6P 205504-46-7P 205504-49-0P
205504-50-3P 205504-51-4P 205504-52-5P
205504-55-8P 205504-56-9P 205504-57-0P
205504-58-1P 205504-59-2P 205504-60-5P
205504-61-6P 205504-62-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)

RN 205504-40-1 HCAPLUS

CN Propanamide, N-hydroxy-3-[(4-methoxyphenyl)sulfonyl]-2-[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-41-2 HCAPLUS
CN Propanamide, 3-[(4-chlorophenyl)sulfonyl]-2-[[(4-chlorophenyl)sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 205504-42-3 HCAPLUS
CN Propanamide, 3-[(4-bromophenyl)sulfonyl]-2-[[(4-bromophenyl)sulfonyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 205504-45-6 HCAPLUS
CN Propanamide, N-hydroxy-3-[(4-methylphenyl)sulfonyl]-2-[[(4-methylphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-46-7 HCAPLUS
CN Propanamide, N-hydroxy-3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



RN 205504-49-0 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-50-3 HCAPLUS
CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-51-4 HCAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-52-5 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-55-8 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-56-9 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 205504-57-0 HCAPLUS
CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-58-1 HCAPLUS
CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-N-hydroxy-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 205504-59-2 HCAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-60-5 HCAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 205504-61-6 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 205504-62-7 HCAPLUS
CN 1-Imidazolidinepropanamide, N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-4,4-dimethyl-2,5-dioxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT **205504-67-2P 205504-68-3P 205504-70-7P**
205504-74-1P 205504-87-6P 205504-88-7P
205504-90-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)
RN 205504-67-2 HCAPLUS
CN Propanoic acid, 3-[(4-methoxyphenyl)thio]-2-[[(4-methoxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 205504-68-3 HCAPLUS
CN Propanoic acid, 3-[(4-methoxyphenyl)sulfonyl]-2-[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-70-7 HCAPLUS
CN Propanoic acid, 3-[(4-chlorophenyl)sulfonyl]-2-[[(4-chlorophenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-74-1 HCAPLUS
CN Propanoic acid, 3-[(4-methylphenyl)sulfonyl]-2-[[(4-methylphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 205504-87-6 HCAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-methoxyphenyl)thio]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-88-7 HCAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 205504-90-1 HCAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-2,5-dioxo- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:549278 HCAPLUS
DOCUMENT NUMBER: 127:161589
TITLE: Preparation of substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds for inhibiting the prodn. or physiol. effects of TNF and cAMP phosphodiesterase.
INVENTOR(S): Groneberg, Robert D.; Neuenschwander, Kent W.; Djuric, Stevan W.; Mcgeehan, Gerard M.; Burns, Christopher J.; Condon, Steven M.; Morrissette, Matthew M.; Salvino, Joseph M.; Scotese, Anthony C.; Ullrich, John W.; et al.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA; Groneberg, Robert D.; Neuenschwander, Kent W.; Djuric, Stevan W.; Mcgeehan, Gerard M.; Burns, Christopher J.; Condon, Steven M.; Morrissette, Matthew M.
SOURCE: PCT Int. Appl., 251 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724117	A1	19970710	WO 1997-US264	19970102
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9715298	A1	19970728	AU 1997-15298	19970102
EP 871439	A1	19981021	EP 1997-901388	19970102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

JP 2000503012	T2	20000314	JP 1997-524642		19970102
US 6057369	A	20000502	US 1997-928943		19970912
US 6133409	A	20001017	US 1998-103872		19980624
US 6392010	B1	20020521	US 1999-469829		19991222
PRIORITY APPLN. INFO.:			US 1996-9484P	P	19960102
			US 1996-32453P	P	19961219
			US 1996-33881P	P	19961224
			WO 1997-US264	W	19970102
			US 1997-928943	A2	19970912
			WO 1997-US23920	A2	19971217
			US 1998-103872	A2	19980624
			WO 1999-US14251	A2	19990623

OTHER SOURCE(S): MARPAT 127:161589

AB The title compds. HONHCOCpR1R2CR3R4[S(O)n]qCmR5R6Ar [I; R1 = H, optionally substituted alkyl, alkenyl, or cycloalkyl, etc.; R2, R4-R6 = H, optionally substituted alkyl, etc.; R3 = optionally substituted alkyl, alkenyl, cycloalkenyl, or cycloalkyl, etc.; Ar = (un)substituted aryl or heteriaryl; n = 0-2; m = 0-1; p = 0-1; q = 0-1] are prepd. I, possessing tumor necrosis factor (TNF), matrix metalloproteinase (MMP), and cAMP phosphodiesterase inhibitory activity, are useful for prevention and treatment of a patient suffering from a disease state assocd. with a physiol. detrimental excess of tumor necrosis factor (TNF) and disease states including inflammatory and autoimmune diseases, etc. Thus, C6H5(CH2)4CH(SO2C6H5)CH2CO2H (prepn. given) was treated with (COCl)2 and then reacted with TMSONH2 to give the title compd. C6H5(CH2)4CH(SO2C6H5)CH2CONHOH.

IT **193550-69-5P 193550-70-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compds. for inhibiting the prodn. or physiol. effects of TNF and cAMP phosphodiesterase.)

RN 193550-69-5 HCAPLUS

CN Benzeneheptanoic acid, .beta.-[(4-methoxyphenyl)sulfonyl]-.alpha.-[(phenylthio)methyl]-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 193550-70-8 HCAPLUS

CN Benzeneheptanamide, N-hydroxy-.beta.-[(4-methoxyphenyl)sulfonyl]-.alpha.-[(phenylthio)methyl]-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L12 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:531906 HCAPLUS
DOCUMENT NUMBER: 113:131906
TITLE: The synthesis of butenolide .alpha.-formyl acetals
AUTHOR(S): Kejian, Chen; Sanner, Mark A.; Carlson, Robert M.
CORPORATE SOURCE: Dep. Chem., Univ. Minnesota, Duluth, MN, 55812, USA
SOURCE: Synthetic Communications (1990), 20(6), 901-6
CODEN: SYNCAV; ISSN: 0039-7911
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:131906
AB The dianion generated from 3-phenylthio-2-(phenylthiomethyl)propenoic acid adds to a series of carbonyl compds. to give, after methanolysis, .alpha.-dimethoxymethyl-.alpha.-butenolides.
IT **92806-66-1**
RL: PROC (Process)
(conversion of, to butenolide formyl acetals)
RN 92806-66-1 HCAPLUS
CN Propanoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1984:591266 HCAPLUS
DOCUMENT NUMBER: 101:191266
TITLE: Preparation of tert-butyl 2-(phenylthiomethyl)propenoate, tert-butyl 3-(phenylthio)-2-(phenylthiomethyl)propenoate and related compounds
AUTHOR(S): Haynes, Richard K.; Katsifis, Andrew; Vonwiller, Simone C.
CORPORATE SOURCE: Dep. Org. Chem., Univ. Sydney, 2006, Australia
SOURCE: Aust. J. Chem. (1984), 37(7), 1571-8
CODEN: AJCHAS; ISSN: 0004-9425
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 101:191266
AB The prepn. of tert-Bu 2-(phenylthiomethyl)propenoate, tert-Bu and Me 3-(phenylthio)-2-(phenylthiomethyl)propenoate, the corresponding carboxylic acids, and 3-(phenylthio)-2-(phenylsulfinylmethyl)propenoate from 3-bromo-2-(bromomethyl)propionic acid is described.
IT **92806-66-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and attempted chlorination of)
RN 92806-66-1 HCAPLUS
CN Propanoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



IT **92806-59-2P 92806-72-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 92806-59-2 HCAPLUS
CN 2-Propenoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 92806-72-9 HCAPLUS
CN 2-Propenoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L12 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1972:528090 HCAPLUS
DOCUMENT NUMBER: 77:128090
TITLE: Intermediates for fiber reactive azo dyes
INVENTOR(S): Schuendehuette, Karl Heinz; Grassmann, Dietrich
PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.
SOURCE: Ger. Offen., 20 pp. Division of Ger. offen. 2,057,867.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2064883	A	19720622	DE 1970-2064883	19701125

AB .alpha.-[(Phenylsulfonyl)methyl]acrylic acid (I) [36526-15-5], .beta.,.beta.'-bis(phenylsulfonyl)isobutyric acid (II) [**36525-59-4**], .alpha.-[(methylsulfonyl)methyl]acrylic acid (III) [36525-60-7], and .beta.,.beta.'-bis(methylsulfonyl)isobutyric acid (IV) [36525-61-8] were prepd. and used in the prepn. of fiber-reactive azo dyes, e.g. azo dye (V) [36525-69-6]. Thus, refluxing (BrCH2)2CHCO2H and PhSO2Na in EtOH gave II. I was similarly prepd. Heating (MeSCH2)2CHCO2H in aq. HOAc contg. H2O2 at 80-90.deg. gave III. Reaction of (BrCH2)2CHCO2Et with MeSH, oxidn. with H2O2 in aq. HOAc, and sapon. with aq. HCl gave IV. Reaction of VI with (PhSO2CH2)2CHCOCl gave V, bluish red on wool.

IT **36525-59-4P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)
RN 36525-59-4 HCAPLUS
CN Propanoic acid, 3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1972:516021 HCAPLUS
DOCUMENT NUMBER: 77:116021
TITLE: Fiber-reactive dyes
INVENTOR(S): Suendehuette, Karl Heinz; Grassmann, Dietrich
PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.
SOURCE: Ger. Offen., 160 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2057867	A	19720615	DE 1970-2057867	19701125
NL 7116048	A	19720529	NL 1971-16048	19711122
IT 946087	A	19730521	IT 1971-31510	19711123
BE 775772	A1	19720524	BE 1971-110871	19711124
GB 1366514	A	19740911	GB 1971-54612	19711124
FR 2144185	A5	19730209	FR 1971-42233	19711125

PRIORITY APPLN. INFO.: DE 1970-2057867 19701125

AB Sixty-eight azo, disazo, metallized azo, anthraquinone, Cu phthalocyanine, and nitro dyes contg. NHCOCH(CH2X)2 (X = Br, NMe2, SO2Ph) or NHCOC(:CH2)CH2Y groups (Y = pyridinium, carboxypyridinium, triethylenediammonium, N+Et3, SO2Ph) were prepd. and used to dye cellulose, nylon, and wool. Prepn. of starting materials contg. the fiber-reactive groups is also described. For example, p-H2NC6H4SO3Na was diazotized and coupled with 1,8-H2NC10H5SO3H and the intermediate azo compd. was condensed with (BrCH2)2CHCOCl to give a reactive azo dye (I) [36339-55-6].

IT **36525-59-4P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)
RN 36525-59-4 HCAPLUS
CN Propanoic acid, 3-(phenylsulfonyl)-2-[(phenylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



=> fil caold
FILE 'CAOLD' ENTERED AT 08:18:32 ON 22 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=> s l2
L13 0 L2

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:23:00 ON 22 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Oct 2002  VOL 137 ISS 17
FILE LAST UPDATED: 21 Oct 2002  (20021021/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=>
=>

=> d stat que
L1              STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE
L2 241 SEA FILE=REGISTRY SSS FUL L1
L3 STR



REP G1=(0-1) N
VAR G2=16/18/21/24/25/27/29/31/32
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE
L4 (241)SEA FILE=REGISTRY SSS FUL L3
L5 STR



REP G1=(0-1) N
VAR G2=16/18/21/24/25/27/29/31/32
VAR G3=39/46/47/48
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE
L6 100 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L7 STR



VAR G2=16/18/21/24/25/27/29/31/32

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L9	184	SEA FILE=REGISTRY	SSS FUL L7		
L10	12	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L2
L11	3	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L6
L12	9	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L10 NOT L11
L18	16	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L9
L19	4	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L18 NOT (L11 OR L12)

=> d ibib abs hitstr l19 1-4

L19 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:338556 HCAPLUS
DOCUMENT NUMBER: 127:50112
TITLE: Free radical addition reactions of allylic sulfones to alkenes
AUTHOR(S): Harvey, Iain W.; Phillips, Eifion D.; Whitham, Gordon H.
CORPORATE SOURCE: Dyson Perrins Laboratory, University of Oxford, OXFORD, OX1 3QY, UK
SOURCE: Tetrahedron (1997), 53(18), 6493-6508
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:50112

AB Intermol. radical reactions involving formal addn. of the sulfonyl and allyl fragments of an allylic sulfone across the double bond of an alkene are described. Reactions are most successful when the allylic sulfone has an electron withdrawing group at the 2-position. Only monosubstituted alkenes give useful yields of adducts, though both electron withdrawing and electron donating substituents are effective.

IT **191152-59-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and free radical addn. reactions of allylic sulfones to alkenes)

RN 191152-59-7 HCAPLUS
CN Pentanedioic acid, 4-methylene-2,2-bis[[(4-methylphenyl)sulfonyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:494702 HCAPLUS
DOCUMENT NUMBER: 119:94702
TITLE: Preparation of functionalized Z-olefins using 1,1-dimetalloalkanes
AUTHOR(S): Tucker, Charles E.; Knochel, Paul
CORPORATE SOURCE: Dep. Chem., Univ. Michigan, Ann Arbor, MI, 48109, USA
SOURCE: Synthesis (1993), (5), 530-6
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 119:94702

AB 1,1-Dimetalloalkanes CH2:CRCH2CHR1CH(MgBr)ZnBr (R = H, R1 = H, n-C6H13; R = Bu, R1 = H), obtained by the allylzincation of alkenylmagnesium compds., react smoothly with various functionalized alkylidenemalonates providing functionalized Z-olefins (Z)-CH2:CRCH2CHR1CH:CHR2 [R2 = (CH2)3CO2Et, cyclohexyl, PhSiMe2, etc.] in good yields. If dimenthyl alkylidenemalonates are used, then excellent stereoselectivies are obsd. (92:8 to 100:0). An application to a short stereospecific synthesis of an insect pheromone [(Z)-7-dodecenyl acetate] is described (>99.9% Z, 70% overall yield).

IT **130247-47-1P 149221-99-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with zinc-copper reagent)

RN 130247-47-1 HCAPLUS
CN Propanedioic acid, [(phenylsulfonyl)methylene]-, dicyclohexyl ester (9CI) (CA INDEX NAME)



RN 149221-99-8 HCAPLUS
CN Propanedioic acid, [(phenylsulfonyl)methylene]-, bis[5-methyl-2-(1-methylethyl)cyclohexyl] ester, [1R-[1.alpha.(1R*,2S*,5R*),2.beta.,5.alpha.]]- (9CI) (CA INDEX NAME)



L19 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:655652 HCAPLUS
DOCUMENT NUMBER: 115:255652
TITLE: Stereo- and regioselective synthesis of polyfunctionalized cyclopropanes
AUTHOR(S): Tanaka, Kazuhiko; Matsuura, Hideki; Funaki, Ikuo; Suzuki, Hitomi
CORPORATE SOURCE: Fac. Sci., Kyoto Univ., Kyoto, 606, Japan
SOURCE: Journal of the Chemical Society, Chemical Communications (1991), (17), 1145-6
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:255652
GI



I

AB The reaction of 3-phenylthio-2-(phenylthiomethyl)propanal (I) with organolithium reagents provides a stereo- and regioselective one-pot route to polyfunctionalized cyclopropane derivs. E.g., reaction of I with MeLi, followed by BuLi and quenching with H2O, gave cyclopropylethanol deriv. I stereoselectively.
IT **92806-63-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(redn. of)
RN 92806-63-8 HCAPLUS
CN Propanoic acid, 3-(phenylthio)-2-[(phenylthio)methyl]-, methyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:610954 HCAPLUS
DOCUMENT NUMBER: 113:210954
TITLE: The olefination of functionalized alkylidenemalonates by 1,1-dimetalloalkanes: a new chemo- and stereoselective preparation of functionalized olefins
AUTHOR(S): Tucker, Charles E.; Rao, S. Achyutha; Knochel, Paul
CORPORATE SOURCE: Dep. Chem., Univ. Michigan, Ann Arbor, MI, 48109, USA
SOURCE: Journal of Organic Chemistry (1990), 55(20), 5446-8
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:210954
AB Polyfunctional alkylidenemalonates were converted under very mild conditions (-20.degree., 10 min) and in excellent yields (76-91%) to highly functionalized olefins by reaction with 1-magnesia-1-zincaalkenes. The newly formed double bond has mainly the Z configuration (typically,

Z:E ratios of 80:20). The nature of the alkylidenemalonate and 1,1-dimetalloalkane substituents influence the Z/E ratio, and a ratio up to 100:0 could be reached. The polyfunctional alkylidenemalonates were prepd. by a new efficient method using the addn. of highly functionalized copper-zinc reagents to [(phenylsulfonyl)methylidene]malonates 9-30.degree., 1h, 40-90% yield). An application of this methodol. to the prepn. of the insect pheromone (Z)-1-acetoxy-7-dodecene is reported (2 steps, 70% overall yield, >99.9% Z isomer).

IT **130247-47-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction with copper-zinc reagents)

RN 130247-47-1 HCAPLUS

CN Propanedioic acid, [(phenylsulfonyl)methylene]-, dicyclohexyl ester (9CI) (CA INDEX NAME)